Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRIAN R WEBSTER

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1124129671
CMS profile
187421
Location
WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$166.49

11 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $166.49 11

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRIAN R WEBSTER

NPI 1124129671 · CMS profile ID 187421

Allopathic & Osteopathic Physicians / Internal Medicine

WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124129671?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRIAN R WEBSTER, NPI 1124129671, CMS profile ID 187421. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124129671?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). BRIAN R WEBSTER, NPI 1124129671, CMS profile ID 187421. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124129671?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
BRIAN R WEBSTER, NPI 1124129671, CMS profile ID 187421, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1124129671?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

11 matching records · $166.49 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 11 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–11 of 11.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $15.6012/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811261289 CMS
Novo Nordisk Inc $17.3912/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811548789 CMS
Abbott Laboratories $13.4811/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815869547 CMS
Optinose US, Inc. $12.1611/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851668445 CMS
Novo Nordisk Inc $15.2311/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810886889 CMS
Novo Nordisk Inc $15.8110/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811087451 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.8209/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850189075 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.1208/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763729354 CMS
Esperion Therapeutics, Inc. $12.2108/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838434275 CMS
Amarin Pharma Inc. $15.8005/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815238247 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.8702/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763729356 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,614.26 105
PY2020 $344.12 25
PY2021 $166.49 11
PY2022 $147.76 12
PY2023 $45.48 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,179,650.03 45
PY2024 Principal investigator $1,336,794.36 51
PY2023 Recipient $628.25 1
PY2023 Principal investigator $421,175.77 35
PY2022 Principal investigator $414,800.07 178
PY2021 Principal investigator $249,631.83 98
PY2020 Principal investigator $39,638.70 30
PY2019 Principal investigator $10,918.41 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

178 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $2,059.00 12/27/2022 Non-covered Recipient Entity
Innovo Rsrch Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885224125
Principal investigator 1 Janssen Research & Development, LLC $6,652.00 12/16/2022 Non-covered Recipient Entity
Innovo Rsrch Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885224127
Principal investigator 1 GlaxoSmithKline, LLC. $1,102.50 11/09/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 943976419
Principal investigator 1 GlaxoSmithKline, LLC. $3,729.61 11/04/2022 Non-covered Recipient Entity
INNOVO RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 965505895
Principal investigator 1 GlaxoSmithKline, LLC. $630.00 10/25/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 943976409
Principal investigator 1 GlaxoSmithKline, LLC. $1,091.70 10/25/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 943976431
Principal investigator 1 GlaxoSmithKline, LLC. $619.20 10/25/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 943976451
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,857.25 10/24/2022 Non-covered Recipient Entity
INNOVO RESEARCH LLC
A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies AZD8895 and AZD1061 for Post-exposure Prophylaxis of COVID-19 No dispute reported 06/30/2026 965526993
Principal investigator 1 Esperion Therapeutics, Inc. $239.00 10/20/2022 Non-covered Recipient Entity
WILMINGTON HEALTH PLLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947291341
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 10/10/2022 Non-covered Recipient Entity
Innovo Research LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910098703
Principal investigator 1 Alnylam Pharmaceuticals Inc. $800.00 10/10/2022 Non-covered Recipient Entity
Innovo Research LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910098705
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,000.00 10/10/2022 Non-covered Recipient Entity
Innovo Research LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910098707
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,200.00 10/10/2022 Non-covered Recipient Entity
Innovo Research LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910098709
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,500.00 10/10/2022 Non-covered Recipient Entity
Innovo Research LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910098711
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 10/10/2022 Non-covered Recipient Entity
Innovo Research LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910098729
Principal investigator 1 PFIZER INC. $450.00 10/08/2022 Non-covered Recipient Entity
Innovo Research Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 949789133
Principal investigator 1 GlaxoSmithKline, LLC. $787.50 10/03/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 943976435
Principal investigator 1 GlaxoSmithKline, LLC. $2,047.50 09/27/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 943976417
Principal investigator 1 GlaxoSmithKline, LLC. $2,205.00 09/27/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 943976427
Principal investigator 1 GlaxoSmithKline, LLC. $1,102.50 09/27/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 943976449
Principal investigator 1 GlaxoSmithKline, LLC. $16,524.33 09/22/2022 Non-covered Recipient Entity
INNOVO RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943976481
Principal investigator 1 Esperion Therapeutics, Inc. $1,446.00 09/19/2022 Non-covered Recipient Entity
WILMINGTON HEALTH PLLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947289659
Principal investigator 1 GlaxoSmithKline, LLC. $1,260.00 09/01/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 943976429
Principal investigator 1 GlaxoSmithKline, LLC. $1,102.50 09/01/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 943976433
Principal investigator 1 GlaxoSmithKline, LLC. $945.00 09/01/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 943976453
Principal investigator 1 Esperion Therapeutics, Inc. $239.00 08/24/2022 Non-covered Recipient Entity
WILMINGTON HEALTH PLLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947288745
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 08/07/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060361
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 08/07/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060371
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 08/07/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060379
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 08/07/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060389
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 08/07/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060399
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 08/07/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060407
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 08/07/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060415
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 08/07/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060425
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 08/07/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060433
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 08/07/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060443
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 08/07/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060451
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 08/07/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060461
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060467
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060477
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060485
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060495
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060503
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060511
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060521
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060529
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060539
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060549
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060557
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910060565
Principal investigator 1 Janssen Research & Development, LLC $9,687.00 07/22/2022 Non-covered Recipient Entity
Innovo Rsrch Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885224123
Principal investigator 1 GlaxoSmithKline, LLC. $630.00 07/20/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 943976437
Principal investigator 1 PFIZER INC. $10,197.00 07/01/2022 Non-covered Recipient Entity
Innovo Research Inc
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949806891
Principal investigator 1 PFIZER INC. $14,480.85 07/01/2022 Non-covered Recipient Entity
Innovo Research Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 949806893
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084209
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084216
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084225
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084233
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084241
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084249
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084257
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084265
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084273
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084283
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084293
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084301
Principal investigator 1 GlaxoSmithKline, LLC. $630.00 06/22/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 943976421
Principal investigator 1 GlaxoSmithKline, LLC. $787.50 06/22/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 943976423
Principal investigator 1 GlaxoSmithKline, LLC. $787.50 06/22/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 943976445
Principal investigator 1 GlaxoSmithKline, LLC. $630.00 06/22/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 943976455
Principal investigator 1 PFIZER INC. $10,297.00 06/22/2022 Non-covered Recipient Entity
Innovo Research Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 949813317
Principal investigator 1 Janssen Research & Development, LLC $21,144.00 06/17/2022 Non-covered Recipient Entity
Qcare Site Svcs Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885229507
Principal investigator 1 Janssen Research & Development, LLC $21,144.00 06/17/2022 Non-covered Recipient Entity
Qcare Site Svcs Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885229515
Principal investigator 1 GlaxoSmithKline, LLC. $1,417.50 06/08/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 943976411
Principal investigator 1 GlaxoSmithKline, LLC. $945.00 06/08/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 943976415
Principal investigator 1 GlaxoSmithKline, LLC. $2,362.50 06/08/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 943976439
Principal investigator 1 GlaxoSmithKline, LLC. $2,047.50 06/08/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 943976441
Principal investigator 1 GlaxoSmithKline, LLC. $787.50 06/08/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 943976447
Principal investigator 1 GlaxoSmithKline, LLC. $4,204.34 06/03/2022 Non-covered Recipient Entity
WILMINGTON HEALTH
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943976475
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084109
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084117
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084123
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084133
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084141
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084149
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084157
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084165
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084173
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084181
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084191
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084199
Principal investigator 1 GlaxoSmithKline, LLC. $2,992.50 05/11/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER No dispute reported 06/30/2026 943976425
Principal investigator 1 GlaxoSmithKline, LLC. $1,690.77 05/04/2022 Non-covered Recipient Entity
WILMINGTON HEALTH
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943976461
Principal investigator 1 Janssen Research & Development, LLC $22.00 05/04/2022 Non-covered Recipient Entity
Qcare Site Svcs Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885229505
Principal investigator 1 Janssen Research & Development, LLC $22.00 05/04/2022 Non-covered Recipient Entity
Qcare Site Svcs Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885229513
Principal investigator 1 GlaxoSmithKline, LLC. $1,890.00 05/03/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER No dispute reported 06/30/2026 943976457
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084011
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084019
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084027
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084035
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084043
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084053
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084061
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084069
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084077
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084083
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084091
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084099
Principal investigator 1 Janssen Research & Development, LLC $42,691.00 04/22/2022 Non-covered Recipient Entity
Qcare Site Svcs Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885229503
Principal investigator 1 Janssen Research & Development, LLC $42,691.00 04/22/2022 Non-covered Recipient Entity
Qcare Site Svcs Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885229511
Principal investigator 1 GlaxoSmithKline, LLC. $1,515.60 04/06/2022 Non-covered Recipient Entity
WILMINGTON HEALTH
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943976459
Principal investigator 1 Janssen Research & Development, LLC $6,443.00 04/04/2022 Non-covered Recipient Entity
Qcare Site Svcs Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885229501
Principal investigator 1 Janssen Research & Development, LLC $6,443.00 04/04/2022 Non-covered Recipient Entity
Qcare Site Svcs Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885229509
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083625
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083633
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083641
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083651
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083661
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083669
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083679
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083689
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083699
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083771
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083781
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083787
Principal investigator 1 Janssen Research & Development, LLC $3,504.00 03/28/2022 Non-covered Recipient Entity
Wilmington Hlth Pllc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885229579
Principal investigator 1 GlaxoSmithKline, LLC. $1,063.79 03/25/2022 Non-covered Recipient Entity
WILMINGTON HEALTH
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943976463
Principal investigator 1 Janssen Research & Development, LLC $6,827.00 03/25/2022 Non-covered Recipient Entity
Wilmington Hlth Pllc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885229577
Principal investigator 1 Esperion Therapeutics, Inc. $70.00 03/24/2022 Non-covered Recipient Entity
WILMINGTON HEALTH PLLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257691
Principal investigator 1 GlaxoSmithKline, LLC. $799.99 03/23/2022 Non-covered Recipient Entity
WILMINGTON HEALTH
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943976473
Principal investigator 1 GlaxoSmithKline, LLC. $97.99 03/23/2022 Non-covered Recipient Entity
WILMINGTON HEALTH
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943976479
Principal investigator 1 Janssen Research & Development, LLC $63,942.00 03/23/2022 Non-covered Recipient Entity
Wilmington Hlth Pllc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885229575
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,252.95 03/16/2022 Non-covered Recipient Entity
WILMINGTON HEALTH
A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies AZD8895 and AZD1061 for Post-exposure Prophylaxis of COVID-19 No dispute reported 06/30/2026 914598075
Principal investigator 1 GlaxoSmithKline, LLC. $258.99 03/11/2022 Non-covered Recipient Entity
WILMINGTON HEALTH
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943976477
Principal investigator 1 GlaxoSmithKline, LLC. $2,478.60 03/04/2022 Non-covered Recipient Entity
WILMINGTON HEALTH
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943976471
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083865
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083875
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083923
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083931
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083939
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083947
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083957
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083967
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083977
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083985
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083993
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910084001
Principal investigator 1 Janssen Research & Development, LLC $1,275.00 02/23/2022 Non-covered Recipient Entity
Wilmington Hlth Pllc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885229573
Principal investigator 1 PFIZER INC. $79.00 02/08/2022 Non-covered Recipient Entity
INNOVO RESEARCH WILMINGTON HEALTH
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949813687
Principal investigator 1 GlaxoSmithKline, LLC. $3,747.78 02/02/2022 Non-covered Recipient Entity
WILMINGTON HEALTH
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943976465
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083797
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083805
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083815
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083823
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083831
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083841
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083850
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083859
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083885
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083895
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083903
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910083913
Principal investigator 1 Esperion Therapeutics, Inc. $693.00 01/25/2022 Non-covered Recipient Entity
WILMINGTON HEALTH PLLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947247577
Principal investigator 1 Esperion Therapeutics, Inc. $239.00 01/25/2022 Non-covered Recipient Entity
WILMINGTON HEALTH PLLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947247611
Principal investigator 1 Esperion Therapeutics, Inc. $239.00 01/25/2022 Non-covered Recipient Entity
WILMINGTON HEALTH PLLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947247635
Principal investigator 1 Esperion Therapeutics, Inc. $239.00 01/25/2022 Non-covered Recipient Entity
WILMINGTON HEALTH PLLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947247681
Principal investigator 1 Esperion Therapeutics, Inc. $239.00 01/25/2022 Non-covered Recipient Entity
WILMINGTON HEALTH PLLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947247685
Principal investigator 1 Esperion Therapeutics, Inc. $239.00 01/25/2022 Non-covered Recipient Entity
WILMINGTON HEALTH PLLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947247691
Principal investigator 1 GlaxoSmithKline, LLC. $1,575.00 01/24/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER No dispute reported 06/30/2026 943976413
Principal investigator 1 GlaxoSmithKline, LLC. $2,784.60 01/24/2022 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER No dispute reported 06/30/2026 943976443
Principal investigator 1 GlaxoSmithKline, LLC. $560.19 01/19/2022 Non-covered Recipient Entity
WILMINGTON HEALTH
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943976467
Principal investigator 1 PFIZER INC. $460.00 01/18/2022 Non-covered Recipient Entity
INNOVO RESEARCH WILMINGTON HEALTH
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949812735
Principal investigator 1 PFIZER INC. $56.90 01/18/2022 Non-covered Recipient Entity
INNOVO RESEARCH WILMINGTON HEALTH
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949813689
Principal investigator 1 PFIZER INC. $920.00 01/12/2022 Non-covered Recipient Entity
INNOVO RESEARCH WILMINGTON HEALTH
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949812733
Principal investigator 1 PFIZER INC. $113.80 01/12/2022 Non-covered Recipient Entity
INNOVO RESEARCH WILMINGTON HEALTH
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949812797
Principal investigator 1 Janssen Research & Development, LLC $3,640.00 01/07/2022 Non-covered Recipient Entity
Wilmington Hlth Pllc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885229571
Principal investigator 1 GlaxoSmithKline, LLC. $17,597.91 01/05/2022 Non-covered Recipient Entity
WILMINGTON HEALTH
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943976469
Principal investigator 1 PFIZER INC. $1,694.93 01/04/2022 Non-covered Recipient Entity
Innovo Research Inc
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949715999